{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Citius Pharmaceuticals, Inc.
Is Citius Pharmaceuticals, Inc. technically bullish or bearish?
As of June 9, 2025, the trend is mildly bearish due to daily moving averages and weekly Bollinger Bands indicating bearishness, despite some mildly bullish signals from the MACD and KST, suggesting a cautious approach is advisable.
Who are in the management team of Citius Pharmaceuticals, Inc.?
As of March 2022, Citius Pharmaceuticals, Inc. is led by Executive Chairman Mr. Leonard Mazur and CEO Mr. Myron Holubiak, supported by independent directors including Mr. Suren Dutia, Dr. Eugene Holuka, Mr. William Kane, Mr. Howard Safir, and Ms. Carol Webb.
What does Citius Pharmaceuticals, Inc. do?
Citius Pharmaceuticals, Inc. is a micro-cap specialty pharmaceutical company focused on developing anti-infective products for adjunct cancer care. As of March 2025, it reported a net profit loss of $12 million and has a market cap of $9.54 million.
How big is Citius Pharmaceuticals, Inc.?
As of Jun 18, Citius Pharmaceuticals, Inc. has a market capitalization of 9.54 million, classifying it as a Micro Cap company, with total assets of 116.65 million and shareholder's funds of 70.08 million. The company reported net sales of 0.00 million and a consolidated net profit of -43.44 million for the latest four quarters.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
